Anti-platelet agregation: what did we learn from the evidence?

Abstract

Hyperglycemia and insulin resistance, characteristics of patients with type 2 diabetes mellitus (T2D), produce platelet and endothelial alterations, increasing the risk of thrombotic events. The efficacy and benefit of antiplatelet therapy are well established in patients with atherosclerotic cardiovascular disease. There is little discussion about the combination of low doses of acetylsalicylic acid (ASA) and a P2Y12 receptor inhibitor in the acute setting of a cardiovascular event. Current evidence seeks to answer the question of how long to maintain this double regimen, mainly in patients with a high risk of bleeding. Maintaining dual antiplatelet therapy for at least one year is recommended after an acute event.This time could be shortened for patients with high bleeding risk and extended for a longer period in patients with a high thrombotic risk. In this scenario, rivaroxaban 2.5 mg b.i.d, can be considered.

Keywords

• antiagregación plaquetaria
• tratamiento